Hepatitis B virus (HBV) infects more than 250 million people worldwide and can lead to chronic liver disease and liver cancer ...

Chief, Digestive Disease Institute, North Shore University Hospital-Long Island Jewish Medical Center, Manhasset, New York; Associate Professor of Medicine, New York University School of Medicine, New ...

Researchers at the Kanazawa University Graduate School of Medical Sciences report in PLOS Pathogens a novel role for the ...

Please provide your email address to receive an email when new articles are posted on . AGA guidance strongly recommends antiviral prophylaxis for patients at high risk for hepatitis B reactivation.

Among patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF), treatment with potent, first-line antivirals entecavir (ETV), tenofovir disoproxil fumarate (TDF), or ...

Please provide your email address to receive an email when new articles are posted on . Adjusted analysis demonstrated no association between nucleos(t)ide analogue retreatment and HBsAg seroclearance ...

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts ...

Viral hepatitis is an infection of the liver with one of five strains of the hepatitis virus (A, B, C, D, or E), resulting in liver inflammation and damage. Hepatitis ...

December 7, 2010 (San Jose, California) — A new study examining the prevalence of different hepatitis B virus (HBV) genotypes in a database of approximately 2400 specimens showed approximately equal ...

PBGENE-HBV, the first gene editing therapy designed to treat chronic Hepatitis B by directly targeting HBV cccDNA and integrated HBV DNA, showcased as the final oral presentation in the late-breaking ...